Patient/age (yr) | Disease duration (mo) | Baseline SLEDAI score | Baseline BILAG score | Total cumulative dose of IS | Clinical outcomes after MSCT | Clinical manifestations |
---|---|---|---|---|---|---|
1/46 | 40 | 17 | 12 | CYC 0.8 gm/mo × 28 mo | PCR | LN, A, C, V, H, ANA+, anti-dsDNA+ |
2/37 | 41 | 12 | 12 | CYC 0.8 gm/mo × 35 mo | PCR | A, LN, V, ANA+, anti-dsDNA+, H |
3/21 | 50 | 11 | 9 | MMF 1.5 gm/d × 31 mo | NR | V, LN, C, anti-SM+ |
4/28 | 98 | 9 | 9 | CYC 0.8 gm/mo × 10 mo, CYC 0.8 gm/mo combined with MMF 1.0 gm/d × 28 mo (discontinue), LEF 20 mg/d × 31 mo | MCR | V, A, alopecia, LN, C, ANA+, anti-dsDNA+ |
5/26 | 120 | 12 | 8 | MMF 2.0 gm/d × 50 mo (discontinue), CYC 0.8 gm/mo × 20 mo | NR | V, A, LN, ANA+, anti-dsDNA+ |
6/23 | 15 | 14 | 19 | CYC 0.8 gm/mo × 15 mo, LEF 20 mg/d × 10 mo | NR | V, A, F, LN, P, ANA+, anti-dsDNA+ |
7/20 | 62 | 12 | 18 | MMF 1.5 gm/d × 34 mo (discontinued), CYC 0.8 gm/mo × 24 mo | PCR | A, F, LN, C, P, ANA+ |
8/43 | 26 | 34 | 20 | CYC 0.8 gm/mo × 10 mo (discontinued), LEF 20 mg/d × 10 mo | PCR → R | C, V, LN, A, seizures, ANA+ |
9/36 | 97 | 10 | 26 | CYC 0.8 gm/mo × 29 mo | MCR → R | C, V, A, LN, P, ANA+ |
10/39 | 60 | 10 | 7 | CYC 0.8 gm/mo × 25 mo (discontinued), LEF 20 mg/d × 30 mo | PCR | LN, A, V, ANA+, anti-SM+ |
11/22 | 40 | 8 | 16 | CYC 0.8 gm/mo × 25 mo | NR | LN, C, P, ANA+, anti-dsDNA+ |
12/20 | 50 | 14 | 13 | CYC 0.8 gm/mo × 15 mo (discontinued), VCR 1 mg/week × 4times (discontinued) | NR | A, severe thrombocytopenia, V, F, ANA+, anti-dsDNA+, anti-SM+ |
13/17 | 75 | 7 | 6 | MMF 1.5 gm/d × 13 mo (discontinued), LEF 20 mg/d × 30 mo | NR | Severe thrombocytopenia, LN, A, ANA+, anti-dsDNA+ |
14/21 | 39 | 12 | 11 | CYC 0.8 gm/mo × 17 mo | NR | LN, F, P, A, anti-dsDNA+ |
15/36 | 60 | 10 | 7 | LEF 20 mg/d × 20 mo (discontinued), CYC 0.8 gm/mo × 37 mo | MCR | LN, V, P, A, ANA+, anti-SM+ |
16/16 | 49 | 11 | 15 | CYC 0.8 gm/mo × 17 mo (discontinued), LEF 20 mg/d × 20 mo | NR | LN, A, V, ANA+ |
17/44 | 145 | 4 | 8 | CYC 0.8 gm/mo × 64 mo | NR | LN, A, V, C, ANA+ |
18/44 | 85 | 8 | 9 | CYC 0.8 gm/mo × 40 mo | PCR | A, LN, F, ANA+, anti-dsDNA+ |
19/29 | 86 | 10 | 5 | CYC 0.8 gm/mo × 24 mo | PCR → R | LN, A, P, F, ANA+, anti-dsDNA+ |
20/54 | 264 | 8 | 4 | CYC 0.8 gm/mo × 36 mo (discontinued), MMF 1.5 gm/d × 12  mo, then MMF 1.0 gm/d × 28 mo | MCR | LN, A, V, C, ANA+ |
21/36 | 121 | 13 | 13 | CYC 0.8 gm/mo × 25 mo, LEF 20 mg/d × 40 mo | PCR → R | LN, A, V, C |
22/40 | 24 | 12 | 8 | CYC 0.8 gm/mo × 18 mo | NR | F, V, LN, C, ANA+ |
23/35 | 25 | 14 | 24 | CYC 0.8 gm/mo × 21 mo | NR | F, A, V, LN, P |
24/27 | 48 | 12 | 7 | LEF 20 mg/d × 4 mo (discontinued), CYC 0.8 gm/mo × 40 mo | MCR | LN, F, A, P, ANA+, anti-SM+ |
25/30 | 102 | 10 | 7 | MMF 2.0 gm/d × 6 mo, then tapered to 1.5 gm/d × 36 mo, LEF 20 mg/d × 12 mo, then tapered to 10 mg/d × 59 mo | PCR | V, A, LN, ANA+, anti-dsDNA+ |
26/31 | 62 | 8 | 3 | MMF 1.5 gm/d × 8 mo, then tapered to 1.0 gm/d × 50 mo, LEF 20 mg/d × 19 mo | MCR → R | LN, V, P, ANA+, anti-dsDNA+ |
27/51 | 108 | 13 | 29 | CYC 0.8 gm/mo × 41 mo, CsA 150 mg/d × 30 mo | NR | LN, V, A, C, seizures |
28/50 | 110 | 10 | 11 | LEF 20 mg/d × 39 mo (discontinued), CYC 0.8 gm/mo × 36 mo | MCR | A, V, LN, ANA+ |
29/45 | 102 | 10 | 9 | CYC 1.2 gm/mo × 22 mo | NR | A, V, LN, ANA+, anti-dsDNA+ |
30/33 | 62 | 10 | 9 | CYC 0.8 gm/mo × 21 mo, LEF 20 mg/d × 12 mo | MCR | LN, A, P, C |
31/32 | 156 | 14 | 12 | CYC 0.8 gm/mo × 36 mo (discontinued), MMF 1.5 gm/d × 6 mo, then tapered to 1.0 gm/d × 56 mo | MCR → R | LN, A, C, P |
32/53 | 146 | 12 | 10 | CYC 0.8 gm/mo × 24 mo, then tapered to 0.6 gm/mo × 42 mo, LEF 20 mg/d × 12 mo, then tapered to 10 mg/d × 40 mo | NR | LN, A, C, anti-dsDNA+ |
33/30 | 157 | 8 | 7 | CYC 0.8 gm/mo × 16 mo (discontinued) | NR | V, LN, A, C, H |
34/35 | 123 | 10 | 9 | CYC 0.8 gm/mo × 18 mo, LEF 20 mg/d × 22 mo | NR | LN, A, H, C, ANA+ |
35/33 | 216 | 10 | 3 | CYC 0.8 gm/mo × 26 mo | PCR | F, LN, V, C, A |
36/39 | 99 | 5 | 7 | CYC 0.8 gm/mo × 14 mo | MCR | LN, C, V, anti-dsDNA+ |
37/35 | 109 | 6 | 6 | LEF 20 mg/d × 34 mo | PCR → R | LN, C, H, ANA+ |
38/31 | 160 | 9 | 7 | LEF 20 mg/d × 13 mo (discontinued), CYC 0.8 gm/mo × 35 mo | MCR | LN, C, V, A |
39/50 | 108 | 10 | 12 | CYC 0.8 gm/mo × 14 mo | MCR | F, LN, A, V, C |
40/35 | 96 | 8 | 8 | CYC 0.8 gm/mo × 28 mo (discontinued), LEF 20 mg/d × 7 mo | MCR | LN, V, P, C, ANA+ |